Skip to main content
Premium Trial:

Request an Annual Quote

Highmark Covering Rosetta Genomics' Cancer MDx

NEW YORK (GenomeWeb News) – Rosetta Genomics announced today that its Rosetta Cancer Origin Test has received in-network provider status with Highmark Health Services.

Highmark Health is a subsidiary of Highmark and the fourth-largest Blue Cross Blue Shield-affiliated company, providing coverage for 5.3 million people in Pennsylvania, Delaware, and West Virginia. Its members now have access to Rosetta's test for identifying the tumor origin in cancer of unknown or uncertain primary as an in-network service.

"Over the past six months we have made considerable progress executing credentialing agreements with large, national preferred provider organizations, thereby expanding the coverage for the Rosetta Cancer Origin Test to one in five Americans," Rosetta President and CEO Kenneth Berlin said in a statement. "This is increasingly important as enhanced awareness of our test and the accurate identification of tumor origin in patients with metastatic cancer has resulted in record volumes of samples processed and billed at our CLIA lab over the past three months."

In September Rosetta announced deals covering the Cancer Origin Test with FedMed and Fortified Provider Network.

The Scan

Hormone-Based Gene Therapy to Sterilize Domestic Cat

A new paper in Nature Communication suggests that gene therapy could be a safer alternative to spaying domestic cats.

Active Lifestyle Linked to Type 2 Diabetes Prevention in People at High Genetic Risk

A study in the British Journal of Sports Medicine shows that an active lifestyle goes a long way in type 2 diabetes prevention.

Beneficial, Harmful Effects of Introgression Between Wild and Domesticated European Grapes

A paper in PNAS shows that European wild grapevines were an important resource for improving the flavor of cultivated wine grapes.

Genetic Ancestry of South America's Indigenous Mapuche Traced

Researchers in Current Biology analyzed genome-wide data from more than five dozen Mapuche individuals to better understand their genetic history.